Apricus Biosciences (APRI) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Apricus Biosciences Provides Corporate Update and Third Quarter 2015 Financial Results
November 5, 2015 4:01 PM ESTCompany Continues to Advance Clinical Pipeline
Vitaros Quarterly Unit Sales Increased 146% in Europe
Conference Call / Webcast Today, Thursday, November 5, 2015 at 5:00 p.m. ET
SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the third quarter and year to date ended September 30, 2015 and provided a corporate update on its clinical development plans for the remainder of 2015.
"The third quarter of this year was one of the... More
